KKR Injects $60M In Slayback Pharma
Pharmaceutical research and development company Slayback Pharma LLC said Thursday that it has received a $60 million investment from private equity giant KKR & Co. to help accelerate the development of...To view the full article, register now.
Already a subscriber? Click here to view full article